Sorafenib

Synonyms: 索拉非尼; Bay 43-9006
Sorafenib (Bay 43-9006) 是一种强效的口服多激酶 (tyrosine kinases) 抑制剂,可通过阻断受体酪氨酸激酶 (VEGFR-2、VEGFR-3) 及 RAF 家族激酶的自磷酸化与活性,抑制 RAF/MEK/ERK 和 PI3K/Akt 通路以及 STAT3 磷酸化,并可诱导细胞周期阻滞、细胞自噬 (autophagy) 和细胞凋亡 (apoptosis) 及 PARP 裂解,降低 Bcl-2、Bcl-XL、cyclin D1 蛋白水平,激活 Bak 和 Bax,从而在小鼠和大鼠模型中抑制肿瘤生长和转移,可用于结肠癌、乳腺癌、非小细胞肺癌、卵巢癌、胰腺癌、黑色素瘤、结直肠癌及肝细胞癌等癌症研究。
产品编号: MS-X92288 纯度: 99.84% CAS No.: 284461-73-0 分子式: C21H16ClF3N4O3 分子量: 464.83
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
3-5 天
5g
询价
询价
10g
询价
询价

产品描述

Sorafenib (Bay 43-9006) 是一种强效的口服多激酶 (tyrosine kinases) 抑制剂,可通过阻断受体酪氨酸激酶 (VEGFR-2、VEGFR-3) 及 RAF 家族激酶的自磷酸化与活性,抑制 RAF/MEK/ERK 和 PI3K/Akt 通路以及 STAT3 磷酸化,并可诱导细胞周期阻滞、细胞自噬 (autophagy) 和细胞凋亡 (apoptosis) 及 PARP 裂解,降低 Bcl-2、Bcl-XL、cyclin D1 蛋白水平,激活 Bak 和 Bax,从而在小鼠和大鼠模型中抑制肿瘤生长和转移,可用于结肠癌、乳腺癌、非小细胞肺癌、卵巢癌、胰腺癌、黑色素瘤、结直肠癌及肝细胞癌等癌症研究。

生物实验数据

生物活性 Sorafenib (Bay 43-9006) is a potent, orally active multi-kinase (tyrosine kinases) inhibitor that blocks the autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby inhibiting the RAF/MEK/ERK and PI3K/Akt pathways and STAT3 phosphorylation, and induces cell cycle arrest, autophagy and apoptosis as well as PARP cleavage, decreases Bcl-2, Bcl-XL and cyclin D1 protein levels, and activates Bak and Bax, thus inhibiting tumor growth and metastasis in mouse and rat models; it can be used in cancer research, such as studies on colon cancer, breast cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, melanoma, colorectal cancer and hepatocellular carcinoma.
IC50 & Target B-CPAP cells:1.85 µM, Flt3:58 nM, VEGFR3:20 nM (cell free), BHT-101 cells:2.1 µM, Raf-1:6 nM (cell free), Huh7 cells:5.97 μM, HepG2 cells:7.42 μM, B-Raf V599E:38 nM (cell free), Hep b3B cells:3.31 μM, TPC1 cells:2.6 µM, c-Kit:68 nM (cell free), VEGFR2:90 nM, PDGFRβ:57 nM (cell free), B-Raf:22 nM (cell free), FTC133 cells:2.9 µM
体外研究
(In Vitro)

Sorafenib (0.01-3 μM; 2 h) 在 MDA-MB-231 细胞中选择性抑制 MAPK 通路,而对 PKB 通路没有影响。
Sorafenib (0.01-3 μM; 2 h) 可抑制 MDA-MB-231 人乳腺癌细胞中 MEK 1/2 和 ERK 1/2 的磷酸化 (IC50 分别为 40 nmol/L 和 90 nmol/L),还可抑制 BxPC-3、LOX、HCT 116、HT-29、Colo-205 及 Mia PaCa-2 细胞中 ERK 1/2 的磷酸化,但对 A549 和 NCI-H460 人非小细胞肺癌细胞中 ERK 1/2 的磷酸化无抑制作用。
Sorafenib (0.01-10 μM; 72 h) 可抑制 MDA-MB-231 细胞的增殖,IC50 为 2600 nmol/L。
Sorafenib (8.9 μM) 在人结直肠癌 HCT8 和 HT29 细胞系中的 IC50 为 8.9 μM,且在所有测试孵育方案中均与奥沙利铂和顺铂表现出显著拮抗作用,可降低铂类诱导的细胞毒性。
Sorafenib (4-24 μM; 24 h) 与 Oxaliplatin (MS-L84463) 或 Cisplatin (MS-E94993) 共同孵育时,可降低 HCT8 和 HT29 细胞中 p21Cip1 和 cyclin D1 蛋白的表达。
Sorafenib (24 μM; 4 h) 同时应用时可显著降低 HCT8 和 HT29 细胞中 Cisplatin 和 Oxaliplatin 诱导的 DNA 加合物水平,但在连续应用时则不会影响加合物水平或修复过程。
Sorafenib (0-20 μmol/L; 24-72 h) 可呈时间和剂量依赖性抑制 HCCLM3、HepG2 和大鼠 Morris 3924A (MH) 肝癌细胞系的增殖。
Sorafenib (0-20 μmol/L; 2-24 h) 可在 HCCLM3、HepG2 和 MH 肝癌细胞系中持久抑制 STAT3Y705、STAT3S727、ERK1/2 及 Akt 的磷酸化,并降低 cyclin D1 的表达,且不会改变 JAK2 或 SHP2 的磷酸化水平。
Sorafenib (5 μM; 48 h) 可显著提高 A549、NCI-H460 和 NCI-H1299 非小细胞肺癌 (NSCLC) 细胞的克隆形成能力、肿瘤球形成能力、上调癌细胞中癌症干细胞相关的多能性标志物 Sox2 和 Oct4。
Sorafenib (5 μM; 48 h) 可增加 A549 非小细胞肺癌细胞中 ALDH 阳性癌症干细胞的群体。
Sorafenib (5 μM; 48 h) 可显著增强 NCI-H460 非小细胞肺癌细胞的迁移能力。
Sorafenib (5 μM; 48 h) 可通过下调 E-cadherin、上调 N-cadherin、波形蛋白 (vimentin) 及 MMP2,诱导 NCI-H460 非小细胞肺癌 (NSCLC) 细胞发生上皮间质转化,且可通过增强 AKT 磷酸化激活 AKT 通路。
Sorafenib (5 μM; 48 h) 可在 mRNA 和蛋白水平上调 NCI-H460 和 NCI-H1299 非小细胞肺癌细胞中 STMN1、FOXM1 以及 E2F1 的表达。

Western Blot Analysis

Cell Line: MDA-MB-231
Concentration: 0.01, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time: 2 h
Result: Dose-dependently inhibited basal MEK 1/2 phosphorylation in MDA-MB-231 cells with an IC50 of 40 nmol/L.
Inhibited ERK 1/2 phosphorylation in MDA-MB-231 cells with an IC50 of 90 nmol/L.
Showed no effect on PKB phosphorylation in MDA-MB-231 cells.
Completely blocked activation of the MAPK pathway.

Cell Proliferation Assay

Cell Line: MDA-MB-231
Concentration: 0.01-10 μM
Incubation Time: 72 h
Result: Inhibited MDA-MB-231 cell proliferation with an IC50 of 2600 nmol/L.

Western Blot Analysis

Cell Line: HCT8 and HT29 cells
Concentration: 4, 24 μM
Incubation Time: 24 h
Result: Reduced p21Cip1 protein expression induced by Oxaliplatin or Cisplatin at 4 μM when applied simultaneously.
Completely inhibited platinum-induced p21Cip1 expression at 24 μM when applied simultaneously.
Reduced cyclin D1 expression enhanced by Oxaliplatin when applied simultaneously.
Reduced cdc2 expression enhanced by cisplatin when applied simultaneously.
Showed no effect on these protein levels when applied consecutively after platinum treatment.

Cell Proliferation Assay

Cell Line: HCCLM3, HepG2, MH cells
Concentration: 0, 0.05, 0.1, 1, 5, 10, 20 μmol/L
Incubation Time: 24, 48, 72 h
Result: Inhibited HCC cell growth in a time- and dose-dependent manner across all three cell lines.
Increased inhibition rates with both higher sorafenib concentrations and longer incubation periods.
Exhibited the strongest inhibition at 20 μmol/L after 72 h of treatment.

Western Blot Analysis

Cell Line: HCCLM3, HepG2, MH cells
Concentration: 0, 2, 5, 10, 20 μmol/L
Incubation Time: 2 h (0-20 μmol/L); 2, 6, 12, 24 h (10 μmol/L)
Result: Inhibited phosphorylation of STAT3 at Y705 and S727, as well as phosphorylation of ERK1/2, in a dose-dependent manner after 2 h of treatment across all three cell lines.
Durably inhibited phosphorylation of STAT3 (Y705 and S727) and ERK1/2 for up to 24 h at 10 μmol/L, while total STAT3 protein levels and JAK2 phosphorylation remained unchanged.
Inhibited Akt phosphorylation primarily at 2 μmol/L after 2 h and reduced cyclin D1 protein expression, while leaving SHP2 phosphorylation unchanged.

Western Blot Analysis

Cell Line: A549, NCI-H460, NCI-H1299 cells
Concentration: 5 μM
Incubation Time: 48 h
Result: Upregulated expression levels of Sox2 and Oct4 in all three NSCLC cell lines compared to untreated controls.
Markedly decreased the epithelial marker E-cadherin compared to untreated controls.
Correspondingly increased mesenchymal markers N-cadherin, vimentin, and MMP2 compared to untreated controls. Upregulated the expression of phosphorylated AKT in NCI-H460 cells compared to untreated controls.
Showed no obvious effect on phosphorylated JNK expression compared to untreated controls in NCI-H460 cells.
Showed an increase in phosphorylated ERK expression compared to untreated controls in NCI-H460 cells.

Cell Migration Assay

Cell Line: NCI-H460 cells
Concentration: 5 μM
Incubation Time: 48 h
Result: Resulted in the strongest enhancement of cell migration.
Showed a higher CI (the capacity for cell migration) slope indicating faster migration velocity compared to DMSO-treated controls.

Western Blot Analysis

Cell Line: NCI-H460, NCI-H1299 cells
Concentration: 5 μM
Incubation Time: 48 h
Result: Upregulated STMN1, FOXM1, and E2F1 protein expression in both cell lines compared to untreated controls.
体内研究
(In Vivo)

Sorafenib (7.5-60 mg/kg;口服;每日给药;连续 5 天或 9天) 在小鼠乳腺癌、结肠癌和非小细胞肺癌异种移植模型中,抑制肿瘤生长,抑制 RAF/MEK/ERK 信号通路,并减少血管生成,且未观察到毒性。
Sorafenib (30 mg/kg;灌胃;每日 1 次;从第 17 天到第 38 天) 在原位大鼠 MH 模型中强效抑制肝细胞癌的肿瘤生长和转移,同时诱导肿瘤细胞凋亡并抑制 STAT3、Akt 及 ERK 的磷酸化。
Sorafenib (10 mg/kg;口服;每日一次;连续 2 周) 在 DENA 诱导的白化大鼠肝细胞癌模型中表现出抗肿瘤活性。
Sorafenib (4 mg/kg;腹腔注射;每周 2 次;持续 4 周) 联合瘤内注射 siTUC338,可通过上调 RASAL1 显著降低小鼠 HepG2/Sor 异种移植瘤的肿瘤体积。

Animal Model: Female NCr-nu/nu mice subcutaneously injected with MDA-MB-231 cells
Dosage: 7.5; 15; 30; 60 mg/kg
Administration: p.o.; daily for 5 or 9 days
Result: Produced a 42% reduction in mean tumor weight after 9 days at 30 mg/kg.
Inhibited microvessel area (MVA) and microvessel density (MVD) in tumors, induced extensive tumor necrosis, reduced phosphorylated ERK 1/2 (pERK) levels, and decreased Ki-67 staining at 30 or 60 mg/kg daily for 5 days.
Caused no toxicity in treated group.
Animal Model: Female NCr-nu/nu mice subcutaneously injected with Colo-205, HT-29, and DLD-1 cells
Dosage: 7.5; 15; 30; 60 mg/kg
Administration: p.o.; daily for 5 or 9 days
Result: Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily for 9 days.
Reduced MVA to ~0.4% and MVD to ~80/mm2 at 30 mg/kg daily for 5 days, and reduced MVA to ~0.2% and MVD to ~50/mm2 at 60 mg/kg daily for 5 days relative to vehicle controls.
Detected no reduction in pERK levels at 30 or 60 mg/kg daily for 5 days.
Caused no toxicity in any treated group.\n
Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily for 9 days.
Inhibited MVA and MVD in tumors by 50 to 80%, reduced pERK levels, and inhibited MEK 1/2 phosphorylation at 30 or 60 mg/kg daily for 5 days.
Caused no toxicity in any treated group.
Animal Model: Female NCr-nu/nu mice subcutaneously injected with NCI-H460, and A549 cells
Dosage: 7.5; 15; 30; 60 mg/kg
Administration: p.o.; daily; 9 days
Result: Produced complete tumor stasis during treatment at 30 to 60 mg/kg daily.
Caused no toxicity in any treated group.
Animal Model: Male ACI rats (200-220 g) orthotopic implantated with Morris Hepatoma (MH) fragments
Dosage: 30 mg/kg
Administration: i.g.; once daily from day 17 to day 38
Result: Reduced mean tumor volume to 351.26 mm3 in early treatment group and 2248.33 mm3 in late treatment group.
Prevented lung, lymph node metastasis, peritoneal seeding, and ascites in 10/10 rats in early treatment group, and lymph node metastasis, peritoneal seeding, and ascites in 10/10 rats in late treatment group.
Induced tumor cell apoptosis with an apoptosis index of 0.909.
Reduced phosphorylation of STAT3 (Y705 and S727), Akt, and ERK in tumor tissue.
Decreased cyclin D1 expression.
Did not affect STAT3 mRNA levels, JAK2 phosphorylation, or SHP2 phosphorylation in tumor tissue.
Animal Model: Male albino rats (100-120 g) with Diethyl Nitrosamin (DENA)-induced hepatocellular carcinoma)
Dosage: 10 mg/kg
Administration: p.o.; daily; 2 weeks
Result: Improved survival rate to 83.3%.
Significantly decreased liver index below normal control group level.
Reduced hepatocellular foci size by 34.8% compared to the DENA-only group.
Lowered total hepatic foci count to 10 compared to 18 in the DENA-only group.
Decreased cyclin D1 and β-catenin gene expression.
Reduced liver Bcl-2 protein and liver glutathione (GSH) levels.
Animal Model: Male nude mice (4-6 weeks, 18-20 g) subcutaneously injected with HepG2/Sor cells
Dosage: 4 mg/kg
Administration: i.p.; twice a week; 4 weeks
Result: Achieved statistically significantly lower mean tumor volume compared to sorafenib combined with saline or siNC.
Significantly downregulated TUC338 expression in tumor tissue relative to control groups.
Significantly upregulated RASAL1 mRNA and protein levels in tumor tissue relative to control groups.
性状 固体
颜色 White to off-white

化学信息

分子量 464.83
分子式 C21H16ClF3N4O3
CAS No. 284461-73-0
别名 索拉非尼; Bay 43-9006

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5.9 mg/mL (12.69 mM), Suspension.
10% DMSO+40% PEG300+ 5% Tween 80 + 45% Saline: 10 mg/mL (21.51 mM), Suspension.
10% DMSO+90% Saline: < 10 mg/mL (21.51 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 45 mg/mL (96.81 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.1513 mL10.7566 mL21.5132 mL53.7831 mL
5 mM0.4303 mL2.1513 mL4.3026 mL10.7566 mL
10 mM0.2151 mL1.0757 mL2.1513 mL5.3783 mL
15 mM0.1434 mL0.7171 mL1.4342 mL3.5855 mL
20 mM0.1076 mL0.5378 mL1.0757 mL2.6892 mL
25 mM0.0861 mL0.4303 mL0.8605 mL2.1513 mL
30 mM0.0717 mL0.3586 mL0.7171 mL1.7928 mL
40 mM0.0538 mL0.2689 mL0.5378 mL1.3446 mL
50 mM0.0430 mL0.2151 mL0.4303 mL1.0757 mL
60 mM0.0359 mL0.1793 mL0.3586 mL0.8964 mL
80 mM0.0269 mL0.1345 mL0.2689 mL0.6723 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

索拉非尼;索拉菲尼 相关分类

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础